SoftBank’s SB Management subsidiary, Illumina and Novartis are backing a $375m PIPE supporting the deal, which values the proteomics technology provider at $1.23bn.
SomaLogic, the US-based healthcare management software provider backed by Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics, agreed a reverse takeover on Monday with special purpose acquisition company CM Life Sciences II. The deal gives SomaLogic a pre-transaction enterprise value of approximately $1.23bn and will involve it acquiring the spot on the Nasdaq Capital Market…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.